NCT02128334View on ClinicalTrials.gov

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

CompletedOBSERVATIONAL
Enrollment

645

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Advanced Prostate Carcinoma
Interventions
DRUG

Eligard 45 mg Exposure

Subcutaneous injections

Trial Locations (52)

Unknown

Site RU34 Private Practice, Abakan

Site RU23 Private Practice, Anapa

Site RU33 Private Practice, Belgorod

Site RU27 Private Practice, Irkutsk

Site RU29 Private Practice, Irkutsk

Site RU36 Private Practice, Izhevsk

Site RU60 Private Practice, Kostroma

Site RU10 Private Practice, Krasnodar

Site RU12 Private Practice, Krasnodar

Site RU13 Private Practice, Krasnodar

Site RU9 Private Practice, Krasnodar

Site RU35 Private Practice, Kursk

Site RU1 Private Practice, Moscow

Site RU11 Private Practice, Moscow

Site RU14 Private Practice, Moscow

Site RU15 Private Practice, Moscow

Site RU2 Private Practice, Moscow

Site RU20 Private Practice, Moscow

Site RU3 Private Practice, Moscow

Site RU32 Private Practice, Moscow

Site RU4 Private Practice, Moscow

Site RU42 Private Practice, Moscow

Site RU44 Private Practice, Moscow

Site RU55 Private Practice, Moscow

Site RU56 Private Practice, Moscow

Site RU6 Private Practice, Moscow

Site RU61 Private Practice, Moscow

Site RU7 Private Practice, Moscow

Site RU71 Private Practice, Moscow

Site RU72 Private Practice, Moscow

Site RU8 Private Practice, Moscow

Site RU21 Private Practice, Nizhny Novgorod

Site RU63 Private Practice, Nizhny Novgorod

Site RU64 Private Practice, Nizhny Novgorod

Site RU53 Private Practice, Novosibirsk

Site RU30 Private Practice, Omsk

Site RU18 Private Practice, Orenburg

Site RU66 Private Practice, Orenburg

Site RU68 Private Practice, Oryol

Site RU37 Private Practice, Petrozavodsk

Site RU40 Private Practice, Ryazan

Site RU73 Private Practice, Ryazan

Site RU17 Private Practice, Saint Petersburg

Site RU19 Private Practice, Saint Petersburg

Site RU65 Private Practice, Saint Petersburg

Site RU76 Private Practice, Saint Petersburg

Site RU59 Private Practice, Stavropol

Site RU25 Private Practice, Syktyvkar

Site RU54 Private Practice, Tver'

Site RU26 Private Practice, Yekaterinburg

Site RU43 Private Practice, Yekaterinburg

Site RU58 Private Practice, Yekaterinburg

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02128334 - An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation | Biotech Hunter | Biotech Hunter